middle.news
SomnoMed Surges with 22% Revenue Growth and FDA-Cleared Rest Assure
2:19am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
SomnoMed Surges with 22% Revenue Growth and FDA-Cleared Rest Assure
2:19am on Saturday 30th of August, 2025 AEST
Key Points
Revenue up 22% to $111.5 million, exceeding guidance
EBITDA jumps to $9.2 million from $0.6 million prior year
Positive operating and free cash flow achieved
FDA clearance for Rest Assure oral device with compliance monitoring
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Somnomed (ASX:SOM)
OPEN ARTICLE